50 of 80 patients enrolled in FLASH 2 study Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J. , Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has completed the planned enrollment of 50... Read More

PRINCETON, N.J. , Nov. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2025 . "We remain focused on multiple upcoming milestones before... Read More

Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J. , Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the update of its United States (U.S.) Medical Advisory Board (MAB) for... Read More

FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J. , Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its first Data Monitoring Committee (DMC)... Read More

In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J. , Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the expansion of its European Medical Advisory Board (MAB)... Read More

Cash runway extended through 2026 to fund multiple expected key inflection points PRINCETON, N.J. , Sept. 29, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the closing of its previously announced "reasonable best efforts"... Read More

PRINCETON, N.J. , Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its "reasonable best efforts" public offering with existing and certain healthcare focused institutional investors for the purchase... Read More

Two Year Stability demonstrated in both bivalent and trivalent configurations at temperatures of 40°C / 104°F PRINCETON, N.J. , Sept. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the extended... Read More

PRINCETON, N.J. , Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber , Ph.D., President and Chief Executive Officer, has been invited to deliver a corporate presentation at the upcoming H.C.... Read More

Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food... Read More

PRINCETON, N.J. , Aug. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2025 . "As we quickly approach the latter part of 2025 into 2026, the... Read More

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view... Read More

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the... Read More

Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J. , July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has completed its Phase 2a proof of concept study evaluating... Read More

PRINCETON, N.J. , July 8, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber . The content of this letter is provided below. Dear Friends and... Read More

Active Ingredient Manufacturing Transfer to the U.S. Complete PRINCETON, N.J. , July 1, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its... Read More

PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc . (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company’s Phase 3 FLASH (1 and 2) studies in early stage cutaneous... Read More

PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025 . "Our strategic focus remains on advancing our clinical programs, and... Read More

Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label,... Read More

Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™ compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March 25, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing... Read More

PRINCETON, N.J. , March 21, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2024 . "We remain highly focused on advancing our multiple clinical... Read More

Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J. , March 6, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its lead... Read More

PRINCETON, N.J. , Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc . (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the BIO CEO & Investor Conference. The conference will be held February 10 - 11, 2025 in New... Read More

PRINCETON, N.J. , Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below. Sequire Investor Summit, held January 21 to 23 at Condado... Read More

Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Jan. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating... Read More

FLASH 2 Study opens patient enrollment PRINCETON, N.J. , Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin)... Read More

Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™ PRINCETON, N.J. , Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of the post-treatment data from the open-label study (protocol... Read More

Phase 3 clinical study of HyBryte ™ in CTCL initiating in 2024 PRINCETON, N.J. , Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European Medical Advisory Board (MAB) to provide additional... Read More

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J. , Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its Phase 2 study (protocol number DUS-AUBD-01) evaluating SGX945... Read More

PRINCETON, N.J. , Nov. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2024 . "We remain focused on multiple clinical activities and upcoming... Read More

PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity... Read More

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis PRINCETON, N.J. , Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Patent Office... Read More

PRINCETON, N.J. , Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will be providing a corporate update at the upcoming investor conferences on the dates below. 2024 Maxim Healthcare Virtual Summit, held... Read More

Two Presentations Highlight HyBryte™ Therapy's Improved Response Rates with Extended Treatment and Increased Light Doses PRINCETON, N.J. , Oct. 7, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that two of its lead investigators... Read More

U.S. Expansion of Synthetic Hypericin Active Ingredient Manufacturing PRINCETON, N.J. , Oct. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has established a partnership agreement with Sterling Pharma Solutions... Read More

PRINCETON, N.J. , Sept. 16, 2024 /PRNewswire/ -- Soligenix , Inc. ( Nasdaq : SNGX ) ( Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is pleased to invite investors to a webinar on September 18, 2024 , at 4:15 p.m . ET. The exclusive event, hosted by RedChip Companies, Inc., will feature Soligenix... Read More

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Systems and... Read More

PRINCETON, N.J. , Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2024 . "This is a pivotal time for Soligenix with a great deal of clinical... Read More

Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended... Read More

HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor ® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a... Read More

Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J. , June 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor... Read More

Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J. , May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1... Read More

Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote their shares at the upcoming reconvened meeting... Read More

PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2024 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on May 23, 2024 has been adjourned for the purpose of... Read More

Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J. , May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote "FOR" a Reverse Stock Split. The Company and its Board of Directors... Read More

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an in-depth interview with Dr. Christopher Schaber, President and Chief Executive Officer of Soligenix, Inc. (Nasdaq: SNGX). The late-stage biopharmaceutical company is advancing a broad pipeline of therapeutic and vaccine candidates across its two business segments, emphasizing its strategic focus on diversified drug development. Soligenix has recently... Read More

PRINCETON, N.J. , May 21, 2024 /PRNewswire/ -- Soligenix, Inc. ( Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company's thermostable vaccine technology platform... Read More

Annual Meeting to be held May 23, 2024 PRINCETON, N.J. , May 20, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to participate in the upcoming Annual Meeting of Stockholders to be held virtually at 9:00AM ET... Read More

Published Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results of its compatibility study evaluating HyBryte™ (synthetic... Read More

PRINCETON, N.J. , May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2024 . "Recently we completed a public offering with gross proceeds of... Read More

PRINCETON, N.J. , May 6, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below. Aegis Virtual Conference, held virtually May 7 through 9, 2024 ,... Read More

Includes thermostabilized Ebola vaccines MarVax™ and SuVax™ Includes nanoemulsion adjuvant compatible with lyophilization PRINCETON, N.J. , April 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of... Read More

PRINCETON, N.J. , April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to... Read More

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the... Read More

Provides SuVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United... Read More

Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study PRINCETON, N.J. , April 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that... Read More

PRINCETON, N.J. , March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2023 . "Our primary focus in 2024 continues to be advancing our multiple... Read More

Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J. , Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical... Read More

PRINCETON, N.J. , Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at The Microcap Conference. The conference will be held January 30 and 31, and February 1, 2024 at... Read More

PRINCETON, N.J. , Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet's Disease has received "Fast Track" designation from the U.S.... Read More

Clinical Success Achieved in Second Cohort of Patients PRINCETON, N.J. , Jan. 4, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the... Read More

Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses PRINCETON, N.J. , Jan. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical... Read More

HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J. , Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that an article describing the potential use of HyBryte™ in the treatment... Read More

Pipeline Expansion of Novel Innate Defense Regulator Technology PRINCETON, N.J. , Nov. 30, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug... Read More

PRINCETON, N.J. , Nov. 17, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting"), which was reconvened on November 16, 2023 , has been adjourned for the purpose of... Read More

PRINCETON, N.J. , Nov. 13, 2023 /PRNewswire/ -- Soligenix, Inc. ( Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2023 . "We continue our collaborative discussions with the U.S. Food... Read More

PRINCETON, N.J. , Oct. 20, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting"), which was reconvened on October 18, 2023 , has been adjourned for the purpose of... Read More

PRINCETON, N.J. , Oct. 16, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming ThinkEquity Conference. The conference will be held October 19, 2023 with... Read More

Vaccines stable for at least two years when stored at 40 degrees Celsius / 104 degrees Fahrenheit Only subunit (protein) vaccine platform shown to protect against potentially lethal Ebola and Marburg viruses No cold chain storage and transport required as compared to other filovirus vaccines PRINCETON, N.J. , Sept. 25, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage... Read More

PRINCETON, N.J. , Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 21, 2023 has been adjourned for the purpose... Read More

PRINCETON, N.J. , August 21, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2023 . "During the second quarter we advanced multiple clinical trials,... Read More

Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Aug. 10, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that patient enrollment has been opened for the investigator-initiated study (IIS)... Read More

Clear biological signal demonstrated; additional patients to be enrolled PRINCETON, N.J. , July 11, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the expansion of its Phase 2a trial of SGX302 (synthetic hypericin) for the... Read More

Peptides for specific use in oral mucositis treatment adds to existing composition of matter claims PRINCETON, N.J. , May 16, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted a patent... Read More

PRINCETON, N.J. , May 15, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2023 . "We recently completed a public offering with gross proceeds of... Read More

Update on FDA Meeting Outcome Expected Next Month PRINCETON, N.J. , May 11, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (U.S.) Food and Drug Administration (FDA) has granted a Type A meeting to discuss... Read More

PRINCETON, N.J. , May 9, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously announced public offering of 6,538,500 shares of common stock (or common stock equivalents in lieu thereof) and common... Read More

PRINCETON, N.J. , May 5, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 6,538,500 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to... Read More

Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 4, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a compatibility study evaluating HyBryte™ (synthetic... Read More

Strengthens regulatory and orphan drug development expertise PRINCETON, N.J. , May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Timothy R. Coté, M.D., M.P.H. to its Board of Directors. Dr. Coté is a... Read More

Phase 2/3-Ready Orphan Disease Program Complements Company's Existing Late-Stage Rare Disease Pipeline PRINCETON, N.J. , May 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it has entered into an exclusive option... Read More

Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request PRINCETON, N.J. , April 24, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company has submitted a Type A Meeting Request to the... Read More

PRINCETON, N.J. , April 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company convened a Type A Meeting with the United States (U.S.) Food and Drug Administration (FDA). During the Type A Meeting, representatives... Read More

PRINCETON, N.J. , April 5, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Adopted Names (USAN) Council has approved the use of the nonproprietary name of "hypericin sodium" for the novel active ingredient... Read More

Update on FDA Meeting Outcome Expected by End of April PRINCETON, N.J. , April 3, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (U.S.) Food and Drug Administration (FDA) has granted a Type A meeting to... Read More

PRINCETON, N.J. , March 31, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2022 . Christopher J. Schaber , PhD, President and Chief Executive... Read More

Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request PRINCETON, N.J. , March 9, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company has submitted a Type A Meeting Request to the... Read More

Soligenix intends to seek guidance from the FDA on how to further advance HyBryte ™ towards potential approval PRINCETON, N.J. , Feb. 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (U.S.) Food and Drug... Read More

Common Stock Will Begin Trading on Split-Adjusted Basis on February 10, 2023 PRINCETON, N.J. , Feb. 9, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it intends to effect a reverse stock split of its common stock at a ratio... Read More

Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the upcoming Virtual... Read More

PRINCETON, N.J. , Dec. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share,... Read More

RiVax ® - Vaccinated NHP survival was statistically significantly correlated with an epitope-specific serum assay ("EPICC") prior to challenge Correlates of protection are essential to support approval via the FDA "Animal Rule" PRINCETON, N.J. , Dec. 20, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to... Read More

Study HPN-PSR-01 opens patient enrollment PRINCETON, N.J. , Dec. 19, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that patient enrollment has been opened for its Phase 2a study (protocol number HPN-PSR-01) evaluating SGX302... Read More

PRINCETON, N.J. , Dec. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it submitted a new drug application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for HyBryte ™ (synthetic hypericin) in the... Read More